THE DEAL, AT A GLANCE
2/4 explanations supportedMVRIX
01What it doesEvidence still neededOpen review status ↗
The draft does not assert a business description and correctly notes that the document only provides an infectious-diseases sector label, not what MVRIX makes or provides.
02Who is involvedEvidence still neededOpen review status ↗
The draft does not name investors or assign roles. Its missing reason is supported: the document says 5 investors participated and that MVRIX has 1 institutional investor, but provides no investor names, no arranger/lender distinction, and no previous-round investor details.
03What happenedMVRIX’s latest funding was a Series B round on Sep. 4, 2026; the dollar amount is redacted.Source-grounded · automated review · Explore ↗
04Why it mattersThe round involved five investors, suggesting multiple backers participated in this financing event.Interpretation · Explore ↗
Click a part to explore its evidence. Symbols are conceptual, not financial charts.Original record source ↗
MVRIX · Financing Record
Explore source-linked visual explanations for MVRIX. Unsupported claims are withheld while source review continues.
Record 11635 · Recorded date: 2026-09-04
Explore company records →